Figure S1 from Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity
Year: 2023
Type: other
Abstract: Perceived Stress scores (PSS). A, Waterfall plot showing best response per immune-modified RECIST as demonstrated by percentage (%) decrease in tumor size in the nine evaluable patients on the study reporting different PSS scores at baseline. B, Change in median PSS scores with subsequent visits for patients treated at 3 different dose levels. X-axis shows clinic visits and Y-axis shows the median PSS score. Dose level 1 is propranolol 10 mg BID, dose level 2 is propranolol 20 mg BID and dose level 3 is propranolol 30 mg BID. The numbers of patients at different time points reporting the PSS scores are shown on the graphs.
Authors: Shipra Gandhi, Manu R. Pandey, Kristopher Attwood, Wenyan Ji, Agnieszka K. Witkiewicz, Erik S. Knudsen, Cheryl Allen, Joseph D. Tario, Paul K. Wallace, Carlos D. Cedeno, Maria Levis, Suzanne Stack, Pauline Funchain, Joseph J. Drabick, Mark J. Bucsek, Igor Puzanov, Hemn Mohammadpour, Elizabeth A. Repasky, Marc S. Ernstoff
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362411008